Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 ...

Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder March 5, 2026 7:30 AM ESTCompany ParticipantsMichael Cola - ...

News Commentary - Treatments for Generalized Anxiety Disorder (GAD) are getting better and more accessible, which is good news ...

Anxiety disorders are common. However, anxiety can also be a symptom of a general medical disorder or a side effect of a medication. Those cases must be identified promptly.

The central nervous system therapeutics sector is approaching a commercial inflection point as multiple candidates advance ...

Helus Pharma (HELP) stock falls as the company posts mid-stage trial data for HLP004, a psychedelic-based therapy for generalized anxiety disorder. Read more here.

ORLANDO, FL - March 02, 2026 - PRESSADVANTAGE - WhiteSands Treatment Center has published a new educational resource on ...

Baystreet.ca News Commentary — The convergence of precision medicine, novel mechanisms, and regulatory support is driving a renaissance in neuropsychiatric drug development1. Federal ...

On March 5, 2026, Helus Pharma reported topline Phase 2 signal detection results for its investigational NSA HLP004 in adults with moderate-to-severe generalized anxiety disorder who remained ...

As humans grow older, their emotional stability and sleep patterns can change significantly. For instance, some past studies ...

Fort Myers, Florida - March 03, 2026 - PRESSADVANTAGE - WhiteSands Treatment Center has published a new educational ...

Helus Pharma HELP shares are down on Thursday following the announcement of topline results from a Phase 2 signal detection study for HLP004, a potential treatment for generalized anxiety disorder ...